These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
454 related articles for article (PubMed ID: 10673511)
1. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WK J Clin Oncol; 2000 Feb; 18(4):708-15. PubMed ID: 10673511 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. Fine HA; Wen PY; Maher EA; Viscosi E; Batchelor T; Lakhani N; Figg WD; Purow BW; Borkowf CB J Clin Oncol; 2003 Jun; 21(12):2299-304. PubMed ID: 12805330 [TBL] [Abstract][Full Text] [Related]
3. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. McMeekin DS; Sill MW; Benbrook D; Darcy KM; Stearns-Kurosawa DJ; Eaton L; Yamada SD; Gynecol Oncol; 2007 May; 105(2):508-16. PubMed ID: 17306350 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651 [TBL] [Abstract][Full Text] [Related]
5. Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. Morabito A; Fanelli M; Carillio G; Gattuso D; Sarmiento R; Gasparini G Oncol Rep; 2004 Jan; 11(1):93-5. PubMed ID: 14654909 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR J Neurooncol; 2001 Aug; 54(1):31-8. PubMed ID: 11763420 [TBL] [Abstract][Full Text] [Related]
7. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study. Beauchesne PD; Taillandier L; Bernier V; Carnin C Cancer Chemother Pharmacol; 2009 Jun; 64(1):171-5. PubMed ID: 19352662 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. Turner CD; Chi S; Marcus KJ; MacDonald T; Packer RJ; Poussaint TY; Vajapeyam S; Ullrich N; Goumnerova LC; Scott RM; Briody C; Chordas C; Zimmerman MA; Kieran MW J Neurooncol; 2007 Mar; 82(1):95-101. PubMed ID: 17031553 [TBL] [Abstract][Full Text] [Related]
9. Thalidomide as an anti-angiogenic agent in relapsed gliomas. Short SC; Traish D; Dowe A; Hines F; Gore M; Brada M J Neurooncol; 2001 Jan; 51(1):41-5. PubMed ID: 11349879 [TBL] [Abstract][Full Text] [Related]
10. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Chang SM; Lamborn KR; Malec M; Larson D; Wara W; Sneed P; Rabbitt J; Page M; Nicholas MK; Prados MD Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):353-7. PubMed ID: 15380566 [TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. Jaeckle KA; Hess KR; Yung WK; Greenberg H; Fine H; Schiff D; Pollack IF; Kuhn J; Fink K; Mehta M; Cloughesy T; Nicholas MK; Chang S; Prados M; J Clin Oncol; 2003 Jun; 21(12):2305-11. PubMed ID: 12805331 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma. Chan JK; Manuel MR; Ciaravino G; Cheung MK; Husain A; Teng NN Gynecol Oncol; 2006 Dec; 103(3):919-23. PubMed ID: 16828852 [TBL] [Abstract][Full Text] [Related]
14. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843 [TBL] [Abstract][Full Text] [Related]
15. Radiotherapy in supratentorial gliomas. A study of 821 cases. Heesters M; Molenaar W; Go GK Strahlenther Onkol; 2003 Sep; 179(9):606-14. PubMed ID: 14628126 [TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)]. Afra D; Sipos L; Vitanovics D Ideggyogy Sz; 2002 Jan; 55(1-2):38-44. PubMed ID: 12122942 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Varker KA; Campbell J; Shah MH Cancer Chemother Pharmacol; 2008 Apr; 61(4):661-8. PubMed ID: 17589846 [TBL] [Abstract][Full Text] [Related]
18. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. Groves MD; Puduvalli VK; Chang SM; Conrad CA; Gilbert MR; Tremont-Lukats IW; Liu TJ; Peterson P; Schiff D; Cloughesy TF; Wen PY; Greenberg H; Abrey LE; DeAngelis LM; Hess KR; Lamborn KR; Prados MD; Yung WK J Neurooncol; 2007 Feb; 81(3):271-7. PubMed ID: 17031561 [TBL] [Abstract][Full Text] [Related]
19. Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. Dal Lago L; Richter MF; Cancela AI; Fernandes SA; Jung KT; Rodrigues AC; Costa TD; Di Leone LP; Schwartsmann G Invest New Drugs; 2003 Aug; 21(3):359-66. PubMed ID: 14578685 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. Fulton D; Urtasun R; Forsyth P J Neurooncol; 1996 Feb; 27(2):149-55. PubMed ID: 8699237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]